No retraction, correction or concern found when last checked on Oct 24, 2026.

Nanotherapeutics for Nose-to-Brain Drug Delivery: An Approach to Bypass the Blood Brain Barrier

David Lee, Tamara Minko

Pharmaceutics · 2021 · Review · CC BY

doi:10.3390/pharmaceutics13122049 (opens in a new tab)

Abstract

Treatment of neurodegenerative diseases or other central nervous system (CNS) disorders has always been a significant challenge. The nature of the blood-brain barrier (BBB) limits the penetration of therapeutic molecules to the brain after oral or parenteral administration, which, in combination with hepatic metabolism and drug elimination and inactivation during its journey in the systemic circulation, decreases the efficacy of the treatment, requires high drug doses and often induces adverse side effects. Nose-to-brain drug delivery allows the direct transport of therapeutic molecules by bypassing the BBB and increases drug concentration in the brain. The present review describes mechanisms of nose-to-brain drug delivery and discusses recent advances in this area with especial emphasis on nanotechnology-based approaches.

References 281

1.
Alexander A., Agrawal M., Uddin A., Siddique S., Shehata A.M., Shaker M.A., Ata Ur Rahman S., Abdul M.I.M., Shaker M.A. Recent expansions of novel strategies towards the drug targeting into the brain. Int. J. Nanomed. 2019;14:5895-5909.
Not in our library10.2147/ijn.s210876 (opens in a new tab)
2.
Engelhardt B., Sorokin L. The blood-brain and the blood-cerebrospinal fluid barriers: Function and dysfunction. Semin. Immunopathol. 2009;31:497-511.
Not in our library10.1007/s00281-009-0177-0 (opens in a new tab)
3.
Koutsari C., Dilworth T.J., Holt J., Elshaboury R., Rotschafer J.C., DiPiro J.T., Yee G.C., Posey L., Haines S.T., Nolin T.D., Ellingrod V. Central Nervous System Infections. Pharmacotherapy: A Pathopysiologic Approach, 11e. 2020.
Not in our library
4.
Global mortality from dementia: Application of a new method and results from the Global Burden of Disease Study 2019 · 2021
No notice
5.
Global, regional, and national burden of neurological disorders, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016 · 2019
No notice
6.
Rickards H. Depression in neurological disorders: Parkinson’s disease, multiple sclerosis, and stroke. J. Neurol. Neurosurg. Psychiatry. 2005;76:i48-i52.
Not in our library10.1136/jnnp.2004.060426 (opens in a new tab)
7.
Simonato M., Bennett J., Boulis N.M., Castro M.G., Fink D.J., Goins W.F., Gray S.J., Lowenstein P.R., Vandenberghe L.H., Wilson T.J., et al. Progress in gene therapy for neurological disorders. Nat. Rev. Neurol. 2013;9:277-291.
Not in our library10.1038/nrneurol.2013.56 (opens in a new tab)
8.
Blasi P., Giovagnoli S., Schoubben A., Ricci M., Rossi C. Solid lipid nanoparticles for targeted brain drug delivery. Adv. Drug Deliv. Rev. 2007;59:454-477.
Not in our library10.1016/j.addr.2007.04.011 (opens in a new tab)
9.
Daneman R., Prat A. The blood-brain barrier. Cold Spring Harb. Perspect. Biol. 2015;7:a020412.
Not in our library10.1101/cshperspect.a020412 (opens in a new tab)
10.
Miller D.S. Regulation of P-glycoprotein and other ABC drug transporters at the blood-brain barrier. Trends Pharmacol. Sci. 2010;31:246-254.
Not in our library10.1016/j.tips.2010.03.003 (opens in a new tab)
11.
Löscher W., Potschka H. Blood-brain barrier active efflux transporters: ATP-binding cassette gene family. NeuroRx. 2005;2:86-98.
Not in our library10.1602/neurorx.2.1.86 (opens in a new tab)
12.
Pardridge W.M. The blood-brain barrier: Bottleneck in brain drug development. NeuroRx. 2005;2:3-14.
Not in our library10.1602/neurorx.2.1.3 (opens in a new tab)
13.
Ohtsuki S., Terasaki T. Contribution of carrier-mediated transport systems to the blood-brain barrier as a supporting and protecting interface for the brain; importance for CNS drug discovery and development. Pharm. Res. 2007;24:1745-1758.
Not in our library10.1007/s11095-007-9374-5 (opens in a new tab)
14.
Hersh D.S., Wadajkar A.S., Roberts N., Perez J.G., Connolly N.P., Frenkel V., Winkles J.A., Woodworth G.F., Kim A.J. Evolving Drug Delivery Strategies to Overcome the Blood Brain Barrier. Curr. Pharm. Des. 2016;22:1177-1193.
Not in our library10.2174/1381612822666151221150733 (opens in a new tab)
15.
Barar J., Rafi M.A., Pourseif M.M., Omidi Y. Blood-brain barrier transport machineries and targeted therapy of brain diseases. Bioimpacts. 2016;6:225-248.
Not in our library10.15171/bi.2016.30 (opens in a new tab)
16.
Goncalves R.A., De Felice F.G. The crosstalk between brain and periphery: Implications for brain health and disease. Neuropharmacology. 2021;197:108728.
Not in our library10.1016/j.neuropharm.2021.108728 (opens in a new tab)
17.
Cook A.M., Mieure K.D., Owen R.D., Pesaturo A.B., Hatton J. Intracerebroventricular administration of drugs. Pharmacotherapy. 2009;29:832-845.
Not in our library10.1592/phco.29.7.832 (opens in a new tab)
18.
Review: Deep brain stimulation in Parkinson’s disease · 2009
Not checked
19.
Nishikawa R., Iwata H., Sakata Y., Muramoto K., Matsuoka T. Safety of Gliadel Implant for Malignant Glioma: Report of Postmarketing Surveillance in Japan. Neurol. Med. Chir. 2021;61:536-548.
Not in our library10.2176/nmc.oa.2021-0024 (opens in a new tab)
20.
Shibahara I., Miyasaka K., Sekiguchi A., Ishiyama H., Inukai M., Yasui Y., Watanabe T., Sato S., Hide T., Kumabe T. Long-term follow-up after BCNU wafer implantation in patients with newly diagnosed glioblastoma. J. Clin. Neurosci. 2021;86:202-210.
Not in our library10.1016/j.jocn.2021.01.037 (opens in a new tab)
21.
Pires A., Fortuna A., Alves G., Falcão A. Intranasal drug delivery: How, why and what for? J. Pharm. Pharm. Sci. 2009;12:288-311.
Not in our library10.18433/j3nc79 (opens in a new tab)
22.
Tian L., Shang Y., Chen R., Bai R., Chen C., Inthavong K., Tu J. Correlation of regional deposition dosage for inhaled nanoparticles in human and rat olfactory. Part. Fibre Toxicol. 2019;16:6.
Not in our library10.1186/s12989-019-0290-8 (opens in a new tab)
23.
Dhuria S.V., Hanson L.R., Frey W.H. Intranasal delivery to the central nervous system: Mechanisms and experimental considerations. J. Pharm. Sci. 2010;99:1654-1673.
Not in our library10.1002/jps.21924 (opens in a new tab)
24.
Karakosta P., Alexopoulos A.H., Kiparissides C. Computational model of particle deposition in the nasal cavity under steady and dynamic flow. Comput Methods Biomech Biomed. Engin. 2015;18:514-526.
Not in our library10.1080/10255842.2013.819856 (opens in a new tab)
25.
Lochhead J.J., Thorne R.G. Intranasal delivery of biologics to the central nervous system. Adv. Drug Deliv. Rev. 2012;64:614-628.
Not in our library10.1016/j.addr.2011.11.002 (opens in a new tab)
26.
Kapoor M., Cloyd J.C., Siegel R.A. A review of intranasal formulations for the treatment of seizure emergencies. J. Control. Release. 2016;237:147-159.
Not in our library10.1016/j.jconrel.2016.07.001 (opens in a new tab)
27.
Bourganis V., Kammona O., Alexopoulos A., Kiparissides C. Recent advances in carrier mediated nose-to-brain delivery of pharmaceutics. Eur. J. Pharm. Biopharm. 2018;128:337-362.
Not in our library10.1016/j.ejpb.2018.05.009 (opens in a new tab)
28.
Tailoring Formulations for Intranasal Nose-to-Brain Delivery: A Review on Architecture, Physico-Chemical Characteristics and Mucociliary Clearance of the Nasal Olfactory Mucosa · 2018
No notice
29.
Kim S.J., Byun S.W., Lee S.S. Various tumors in the nasal vestibule. Int. J. Clin. Exp. Pathol. 2013;6:2713-2718.
Not in our library
30.
Illum L. Transport of drugs from the nasal cavity to the central nervous system. Eur. J. Pharm. Sci. 2000;11:1-18.
Not in our library10.1016/s0928-0987(00)00087-7 (opens in a new tab)
31.
Chatterjee B., Gorain B., Mohananaidu K., Sengupta P., Mandal U.K., Choudhury H. Targeted drug delivery to the brain via intranasal nanoemulsion: Available proof of concept and existing challenges. Int. J. Pharm. 2019;565:258-268.
Not in our library10.1016/j.ijpharm.2019.05.032 (opens in a new tab)
32.
Lindsay S.L., McCanney G.A., Willison A.G., Barnett S.C. Multi-target approaches to CNS repair: Olfactory mucosa-derived cells and heparan sulfates. Nat. Rev. Neurol. 2020;16:229-240.
Not in our library10.1038/s41582-020-0311-0 (opens in a new tab)
33.
Rock J.R., Randell S.H., Hogan B.L. Airway basal stem cells: A perspective on their roles in epithelial homeostasis and remodeling. Dis. Model. Mech. 2010;3:545-556.
Not in our library10.1242/dmm.006031 (opens in a new tab)
34.
Lillehoj E.P., Kato K., Lu W., Kim K.C. Cellular and molecular biology of airway mucins. Int. Rev. Cell Mol. Biol. 2013;303:139-202.
Not in our library10.1016/b978-0-12-407697-6.00004-0 (opens in a new tab)
35.
Lillehoj E.R., Kim K.C. Airway mucus: Its components and function. Arch. Pharm. Res. 2002;25:770-780.
Not in our library10.1007/bf02976990 (opens in a new tab)
36.
Fahy J.V., Dickey B.F. Airway mucus function and dysfunction. N. Engl. J. Med. 2010;363:2233-2247.
Not in our library10.1056/nejmra0910061 (opens in a new tab)
37.
Md S., Mustafa G., Baboota S., Ali J. Nanoneurotherapeutics approach intended for direct nose to brain delivery. Drug Dev. Ind. Pharm. 2015;41:1922-1934.
Not in our library10.3109/03639045.2015.1052081 (opens in a new tab)
38.
Stoeckelhuber M., Olzowy B., Ihler F., Matthias C., Scherer E.Q., Babaryka G., Loeffelbein D.J., Rohleder N.H., Nieberler M., Kesting M.R. Immunolocalization of antimicrobial and cytoskeletal components in the serous glands of human sinonasal mucosa. Histol. Histopathol. 2014;29:1315-1324.
Not in our library10.14670/hh-29.1315 (opens in a new tab)
39.
Walker H.K., Walker H.K., Hall W.D., Hurst J.W. Cranial Nerve I: The Olfactory Nerve. Clinical Methods: The History, Physical, and Laboratory Examinations. 1990.
Not in our library
40.
Harkema J.R., Carey S.A., Wagner J.G. The nose revisited: A brief review of the comparative structure, function, and toxicologic pathology of the nasal epithelium. Toxicol. Pathol. 2006;34:252-269.
Not in our library10.1080/01926230600713475 (opens in a new tab)
41.
Trimmer C., Snyder L.L., Mainland J.D. High-throughput analysis of mammalian olfactory receptors: Measurement of receptor activation via luciferase activity. J. Vis. Exp. 2014;88:1-10.
Not in our library10.3791/51640 (opens in a new tab)
42.
Landis M.S., Boyden T., Pegg S. Nasal-to-CNS drug delivery: Where are we now and where are we heading? An industrial perspective. Ther. Deliv. 2012;3:195-208.
Not in our library10.4155/tde.11.149 (opens in a new tab)
43.
Anatomical and Histological Factors Affecting Intranasal Drug and Vaccine Delivery · 2012
No notice
44.
Cowan C.M., Roskams A.J. Apoptosis in the mature and developing olfactory neuroepithelium. Microsc. Res. Tech. 2002;58:204-215.
Not in our library10.1002/jemt.10150 (opens in a new tab)
45.
Crowe T.P., Greenlee M.H.W., Kanthasamy A.G., Hsu W.H. Mechanism of intranasal drug delivery directly to the brain. Life Sci. 2018;195:44-52.
Not in our library10.1016/j.lfs.2017.12.025 (opens in a new tab)
46.
Caggiano M., Kauer J.S., Hunter D.D. Globose basal cells are neuronal progenitors in the olfactory epithelium: A lineage analysis using a replication-incompetent retrovirus. Neuron. 1994;13:339-352.
Not in our library10.1016/0896-6273(94)90351-4 (opens in a new tab)
47.
Mackay-Sim A. Stem cells and their niche in the adult olfactory mucosa. Arch. Ital. Biol. 2010;148:47-58.
Not in our library
48.
Iwai N., Zhou Z., Roop D.R., Behringer R.R. Horizontal basal cells are multipotent progenitors in normal and injured adult olfactory epithelium. Stem. Cells. 2008;26:1298-1306.
Not in our library10.1634/stemcells.2007-0891 (opens in a new tab)
49.
Liang F. Olfactory receptor neuronal dendrites become mostly intra-sustentacularly enwrapped upon maturity. J. Anat. 2018;232:674-685.
Not in our library10.1111/joa.12777 (opens in a new tab)
50.
Chen C.R., Kachramanoglou C., Li D., Andrews P., Choi D. Anatomy and cellular constituents of the human olfactory mucosa: A review. J. Neurol. Surg. B Skull Base. 2014;75:293-300.
Not in our library10.1055/s-0033-1361837 (opens in a new tab)
51.
Maurya D.K., Henriques T., Marini M., Pedemonte N., Galietta L.J., Rock J.R., Harfe B.D., Menini A. Development of the Olfactory Epithelium and Nasal Glands in TMEM16A−/− and TMEM16A+/+ Mice. PLoS ONE. 2015;10:e0129171.
Not in our library10.1371/journal.pone.0129171 (opens in a new tab)
52.
Solbu T.T., Holen T. Aquaporin pathways and mucin secretion of Bowman’s glands might protect the olfactory mucosa. Chem. Senses. 2012;37:35-46.
Not in our library10.1093/chemse/bjr063 (opens in a new tab)
53.
Sun X., Tan Z., Huang X., Cheng X., Yuan Y., Qin S., Wang D., Hu X., Gu Y., Qian W.-J., et al. Direct neuronal reprogramming of olfactory ensheathing cells for CNS repair. Cell Death Dis. 2019;10:646.
Not in our library10.1038/s41419-019-1887-4 (opens in a new tab)
54.
Mittal D., Ali A., Md S., Baboota S., Sahni J.K., Ali J. Insights into direct nose to brain delivery: Current status and future perspective. Drug Deliv. 2014;21:75-86.
Not in our library10.3109/10717544.2013.838713 (opens in a new tab)
55.
Bannister L.H., Dodson H.C. Endocytic pathways in the olfactory and vomeronasal epithelia of the mouse: Ultrastructure and uptake of tracers. Microsc. Res. Tech. 1992;23:128-141.
Not in our library10.1002/jemt.1070230204 (opens in a new tab)
56.
Morrison E.E., Costanzo R.M. Morphology of olfactory epithelium in humans and other vertebrates. Microsc. Res. Tech. 1992;23:49-61.
Not in our library10.1002/jemt.1070230105 (opens in a new tab)
57.
Buchner K., Seitz-Tutter D., Schönitzer K., Weiss D.G. A quantitative study of anterograde and retrograde axonal transport of exogenous proteins in olfactory nerve C-fibers. Neuroscience. 1987;22:697-707.
Not in our library10.1016/0306-4522(87)90366-6 (opens in a new tab)
58.
Selvaraj K., Gowthamarajan K., Karri V. Nose to brain transport pathways an overview: Potential of nanostructured lipid carriers in nose to brain targeting. Artif. Cells Nanomed. Biotechnol. 2018;46:2088-2095.
Not in our library10.1080/21691401.2017.1420073 (opens in a new tab)
59.
Marianecci C., Rinaldi F., Hanieh P.N., Paolino D., Marzio L.D., Carafa M. Nose to Brain Delivery: New Trends in Amphiphile-Based “Soft” Nanocarriers. Curr. Pharm. Des. 2015;21:5225-5232.
Not in our library10.2174/1381612821666150923095958 (opens in a new tab)
60.
Pardeshi C.V., Belgamwar V.S. Direct nose to brain drug delivery via integrated nerve pathways bypassing the blood-brain barrier: An excellent platform for brain targeting. Expert Opin. Drug Deliv. 2013;10:957-972.
Not in our library10.1517/17425247.2013.790887 (opens in a new tab)
61.
Bathla G., Hegde A.N. The trigeminal nerve: An illustrated review of its imaging anatomy and pathology. Clin. Radiol. 2013;68:203-213.
Not in our library10.1016/j.crad.2012.05.019 (opens in a new tab)
62.
Schaefer M.L., Böttger B., Silver W.L., Finger T.E. Trigeminal collaterals in the nasal epithelium and olfactory bulb: A potential route for direct modulation of olfactory information by trigeminal stimuli. J. Comp. Neurol. 2002;444:221-226.
Not in our library10.1002/cne.10143 (opens in a new tab)
63.
Ishikawa T. Axoneme Structure from Motile Cilia. Cold Spring Harb. Perspect. Biol. 2017;9:a028076.
Not in our library10.1101/cshperspect.a028076 (opens in a new tab)
64.
Romanelli M.C., Gelardi M., Fiorella M.L., Tattoli L., Di Vella G., Solarino B. Nasal ciliary motility: A new tool in estimating the time of death. Int. J. Legal Med. 2012;126:427-433.
Not in our library10.1007/s00414-012-0682-x (opens in a new tab)
65.
Kaliner M., Marom Z., Patow C., Shelhamer J. Human respiratory mucus. J. Allergy Clin. Immunol. 1984;73:318-323.
Not in our library10.1016/0091-6749(84)90403-2 (opens in a new tab)
66.
Cone R.A. Barrier properties of mucus. Adv. Drug Deliv. Rev. 2009;61:75-85.
Not in our library10.1016/j.addr.2008.09.008 (opens in a new tab)
67.
Lieleg O., Ribbeck K. Biological hydrogels as selective diffusion barriers. Trends Cell Biol. 2011;21:543-551.
Not in our library10.1016/j.tcb.2011.06.002 (opens in a new tab)
68.
Ugwoke M.I., Agu R.U., Verbeke N., Kinget R. Nasal mucoadhesive drug delivery: Background, applications, trends and future perspectives. Adv. Drug Deliv. Rev. 2005;57:1640-1665.
Not in our library10.1016/j.addr.2005.07.009 (opens in a new tab)
69.
Williams O.W., Sharafkhaneh A., Kim V., Dickey B.F., Evans C.M. Airway mucus: From production to secretion. Am. J. Respir. Cell Mol. Biol. 2006;34:527-536.
Not in our library10.1165/rcmb.2005-0436sf (opens in a new tab)
70.
Merkus F.W., Verhoef J.C., Schipper N.G., Marttin E. Nasal mucociliary clearance as a factor in nasal drug delivery. Adv. Drug Deliv. Rev. 1998;29:13-38.
Not in our library10.1016/s0169-409x(97)00059-8 (opens in a new tab)
71.
Bustamante-Marin X.M., Ostrowski L.E. Cilia and Mucociliary Clearance. Cold Spring Harb. Perspect. Biol. 2017;9:a028241.
Not in our library10.1101/cshperspect.a028241 (opens in a new tab)
72.
Pires P.C., Santos A.O. Nanosystems in nose-to-brain drug delivery: A review of non-clinical brain targeting studies. J. Control. Release. 2018;270:89-100.
Not in our library10.1016/j.jconrel.2017.11.047 (opens in a new tab)
73.
Kozlovskaya L., Abou-Kaoud M., Stepensky D. Quantitative analysis of drug delivery to the brain via nasal route. J. Control. Release. 2014;189:133-140.
Not in our library10.1016/j.jconrel.2014.06.053 (opens in a new tab)
74.
Kuzmov A., Minko T. Nanotechnology approaches for inhalation treatment of lung diseases. J. Control. Release. 2015;219:500-518.
Not in our library10.1016/j.jconrel.2015.07.024 (opens in a new tab)
75.
Shen A.M., Minko T. Pharmacokinetics of inhaled nanotherapeutics for pulmonary delivery. J. Control. Release. 2020;326:222-244.
Not in our library10.1016/j.jconrel.2020.07.011 (opens in a new tab)
76.
Surface-Modified Nanocarriers for Nose-to-Brain Delivery: From Bioadhesion to Targeting · 2018
No notice
77.
Shannahan J. The biocorona: A challenge for the biomedical application of nanoparticles. Nanotechnol. Rev. 2017;6:345-353.
Not in our library10.1515/ntrev-2016-0098 (opens in a new tab)
78.
Pitman M., Larsen J. The characterization of self-assembled nanostructures in whole blood. Anal. Methods. 2020;12:2068-2081.
Not in our library10.1039/d0ay00170h (opens in a new tab)
79.
Understanding the Lipid and Protein Corona Formation on Different Sized Polymeric Nanoparticles · 2020
No notice
80.
Müller L.K., Simon J., Rosenauer C., Mailänder V., Morsbach S., Landfester K. The Transferability from Animal Models to Humans: Challenges Regarding Aggregation and Protein Corona Formation of Nanoparticles. Biomacromolecules. 2018;19:374-385.
Not in our library10.1021/acs.biomac.7b01472 (opens in a new tab)
81.
Chinen A.B., Guan C.M., Ko C.H., Mirkin C.A. The Impact of Protein Corona Formation on the Macrophage Cellular Uptake and Biodistribution of Spherical Nucleic Acids. Small. 2017;13:1603847.
Not in our library10.1002/smll.201603847 (opens in a new tab)
82.
Effects of Titanium Dioxide Nanoparticles Exposure on Human Health—a Review · 2019
No notice
83.
Sahu S.C., Hayes A.W. Toxicity of nanomaterials found in human environment: A literature review. Toxicol. Res. Appl. 2017;1:2397847317726352.
Not in our library10.1177/2397847317726352 (opens in a new tab)
84.
Feng Y., He H., Li F., Lu Y., Qi J., Wu W. An update on the role of nanovehicles in nose-to-brain drug delivery. Drug Discov. Today. 2018;23:1079-1088.
Not in our library10.1016/j.drudis.2018.01.005 (opens in a new tab)
85.
Ray S., Cheng C.A., Chen W., Li Z., Zink J.I., Lin Y.Y. Magnetic Heating Stimulated Cargo Release with Dose Control using Multifunctional MR and Thermosensitive Liposome. Nanotheranostics. 2019;3:166-178.
Not in our library10.7150/ntno.31164 (opens in a new tab)
86.
Wang T., Luo Y. Biological fate of ingested lipid-based nanoparticles: Current understanding and future directions. Nanoscale. 2019;11:11048-11063.
Not in our library10.1039/c9nr03025e (opens in a new tab)
87.
Taratula O., Kuzmov A., Shah M., Garbuzenko O.B., Minko T. Nanostructured lipid carriers as multifunctional nanomedicine platform for pulmonary co-delivery of anticancer drugs and siRNA. J. Control. Release. 2013;171:349-357.
Not in our library10.1016/j.jconrel.2013.04.018 (opens in a new tab)
88.
Chen W., Liu C., Ji X., Joseph J., Tang Z., Ouyang J., Xiao Y., Kong N., Joshi N., Farokhzad O.C., et al. Stanene-Based Nanosheets for β-Elemene Delivery and Ultrasound-Mediated Combination Cancer Therapy. Angew. Chem. Int. Ed. 2021;60:7155-7164.
Not in our library10.1002/anie.202016330 (opens in a new tab)
89.
Formulation of Poloxamers for Drug Delivery · 2018
No notice
90.
Mucosal Applications of Poloxamer 407-Based Hydrogels: An Overview · 2018
No notice
91.
Zhao Y.Z., Li X., Lu C.T., Lin M., Chen L.J., Xiang Q., Zhang M., Jin R.R., Jiang X., Shen X.T., et al. Gelatin nanostructured lipid carriers-mediated intranasal delivery of basic fibroblast growth factor enhances functional recovery in hemiparkinsonian rats. Nanomedicine. 2014;10:755-764.
Not in our library10.1016/j.nano.2013.10.009 (opens in a new tab)
92.
Bondì M.L., Di Gesù R., Craparo E.F. Lipid nanoparticles for drug targeting to the brain. Methods Enzymol. 2012;508:229-251.
Not in our library10.1016/b978-0-12-391860-4.00012-4 (opens in a new tab)
93.
Towards Improvements for Penetrating the Blood–Brain Barrier—Recent Progress from a Material and Pharmaceutical Perspective · 2018
No notice
94.
Dow S. Liposome-nucleic acid immunotherapeutics. Expert Opin. Drug Deliv. 2008;5:11-24.
Not in our library10.1517/17425247.5.1.11 (opens in a new tab)
95.
Garbuzenko O.B., Mainelis G., Taratula O., Minko T. Inhalation treatment of lung cancer: The influence of composition, size and shape of nanocarriers on their lung accumulation and retention. Cancer Biol. Med. 2014;11:44-55.
Not in our library10.7497/j.issn.2095-3941.2014.01.004 (opens in a new tab)
96.
Shah V., Taratula O., Garbuzenko O.B., Patil M.L., Savla R., Zhang M., Minko T. Genotoxicity of different nanocarriers: Possible modifications for the delivery of nucleic acids. Curr. Drug Discov. Technol. 2013;10:8-15.
Not in our library
97.
Sanchez-Purra M., Ramos V., Petrenko V.A., Torchilin V.P., Borros S. Double-targeted polymersomes and liposomes for multiple barrier crossing. Int. J. Pharm. 2016;511:946-956.
Not in our library10.1016/j.ijpharm.2016.08.001 (opens in a new tab)
98.
Dhaliwal H.K., Fan Y., Kim J., Amiji M.M. Intranasal Delivery and Transfection of mRNA Therapeutics in the Brain Using Cationic Liposomes. Mol. Pharm. 2020;17:1996-2005.
Not in our library10.1021/acs.molpharmaceut.0c00170 (opens in a new tab)
99.
Al Asmari A.K., Ullah Z., Tariq M., Fatani A. Preparation, characterization, and in vivo evaluation of intranasally administered liposomal formulation of donepezil. Drug Des. Devel. Ther. 2016;10:205-215.
Not in our library10.2147/dddt.s93937 (opens in a new tab)
100.
Mutlu N.B., Değim Z., Yilmaz Ş., Eşsiz D., Nacar A. New perspective for the treatment of Alzheimer diseases: Liposomal rivastigmine formulations. Drug Dev. Ind. Pharm. 2011;37:775-789.
Not in our library10.3109/03639045.2010.541262 (opens in a new tab)
101.
Hoekman J.D., Srivastava P., Ho R.J. Aerosol-stable peptide-coated liposome nanoparticles: A proof-of-concept study with opioid fentanyl in enhancing analgesic effects and reducing plasma drug exposure. J. Pharm. Sci. 2014;103:2231-2239.
Not in our library10.1002/jps.24022 (opens in a new tab)
102.
Migliore M.M., Vyas T.K., Campbell R.B., Amiji M.M., Waszczak B.L. Brain delivery of proteins by the intranasal route of administration: A comparison of cationic liposomes versus aqueous solution formulations. J. Pharm. Sci. 2010;99:1745-1761.
Not in our library10.1002/jps.21939 (opens in a new tab)
103.
Zheng X., Shao X., Zhang C., Tan Y., Liu Q., Wan X., Zhang Q., Xu S., Jiang X. Intranasal H102 Peptide-Loaded Liposomes for Brain Delivery to Treat Alzheimer’s Disease. Pharm. Res. 2015;32:3837-3849.
Not in our library10.1007/s11095-015-1744-9 (opens in a new tab)
104.
Pashirova T.N., Zueva I.V., Petrov K.A., Lukashenko S.S., Nizameev I.R., Kulik N.V., Voloshina A.D., Almasy L., Kadirov M.K., Masson P., et al. Mixed cationic liposomes for brain delivery of drugs by the intranasal route: The acetylcholinesterase reactivator 2-PAM as encapsulated drug model. Colloids Surf. B Biointerfaces. 2018;171:358-367.
Not in our library10.1016/j.colsurfb.2018.07.049 (opens in a new tab)
105.
Makowski L., Olson-Sidford W., W-Weisel J. Biological and Clinical Consequences of Integrin Binding via a Rogue RGD Motif in the SARS CoV-2 Spike Protein. Viruses. 2021;13:146.
Not in our library10.3390/v13020146 (opens in a new tab)
106.
Solid lipid nanoparticles: A modern formulation approach in drug delivery system · 2009
No notice
107.
Puri A., Loomis K., Smith B., Lee J.H., Yavlovich A., Heldman E., Blumenthal R. Lipid-based nanoparticles as pharmaceutical drug carriers: From concepts to clinic. Crit. Rev. Ther. Drug Carrier Syst. 2009;26:523-580.
Not in our library10.1615/critrevtherdrugcarriersyst.v26.i6.10 (opens in a new tab)
108.
Ghasemiyeh P., Mohammadi-Samani S. Solid lipid nanoparticles and nanostructured lipid carriers as novel drug delivery systems: Applications, advantages and disadvantages. Res. Pharm. Sci. 2018;13:288-303.
Not in our library10.4103/1735-5362.235156 (opens in a new tab)
109.
Badilli U., Gumustas M., Uslu B., Ozkan S.A., Grumezescu A.M. Chapter 9—Lipid-based nanoparticles for dermal drug delivery. Organic Materials as Smart Nanocarriers for Drug Delivery. 2018;369-413.
Not in our library
110.
Sajid M., Cameotra S.S., Ahmad Khan M.S., Ahmad I., Ahmad Khan M.S., Ahmad I., Chattopadhyay D. Chapter 23—Nanoparticle-Based Delivery of Phytomedicines: Challenges and Opportunities. New Look to Phytomedicine. 2019;597-623.
Not in our library
111.
Patel S., Chavhan S., Soni H., Babbar A.K., Mathur R., Mishra A.K., Sawant K. Brain targeting of risperidone-loaded solid lipid nanoparticles by intranasal route. J. Drug Target. 2011;19:468-474.
Not in our library10.3109/1061186x.2010.523787 (opens in a new tab)
112.
Martins S., Sarmento B., Ferreira D.C., Souto E.B. Lipid-based colloidal carriers for peptide and protein delivery--liposomes versus lipid nanoparticles. Int. J. Nanomedicine. 2007;2:595-607.
Not in our library
113.
Agrawal M., Saraf S., Saraf S., Dubey S.K., Puri A., Patel R.J., Ajazuddin, Ravichandiran V., Murty U.S., Alexander A. Recent strategies and advances in the fabrication of nano lipid carriers and their application towards brain targeting. J. Control. Release. 2020;321:372-415.
Not in our library10.1016/j.jconrel.2020.02.020 (opens in a new tab)
114.
Tapeinos C., Battaglini M., Ciofani G. Advances in the design of solid lipid nanoparticles and nanostructured lipid carriers for targeting brain diseases. J. Control. Release. 2017;264:306-332.
Not in our library10.1016/j.jconrel.2017.08.033 (opens in a new tab)
115.
Madane R.G., Mahajan H.S. Curcumin-loaded nanostructured lipid carriers (NLCs) for nasal administration: Design, characterization, and in vivo study. Drug Deliv. 2016;23:1326-1334.
Not in our library10.3109/10717544.2014.975382 (opens in a new tab)
116.
Gupta A., Eral H.B., Hatton T.A., Doyle P.S. Nanoemulsions: Formation, properties and applications. Soft Matter. 2016;12:2826-2841.
Not in our library10.1039/c5sm02958a (opens in a new tab)
117.
Hayes D.G., Ye R., Dunlap R.N., Anunciado D.B., Pingali S.V., O’Neill H.M., Urban V.S. Bicontinuous microemulsions as a biomembrane mimetic system for melittin. Biochim. Biophys. Acta Biomembr. 2018;1860:624-632.
Not in our library10.1016/j.bbamem.2017.11.005 (opens in a new tab)
118.
Nanoemulsion: an advanced mode of drug delivery system · 2014
No notice
119.
Costa C., Moreira J.N., Amaral M.H., Sousa Lobo J.M., Silva A.C. Nose-to-brain delivery of lipid-based nanosystems for epileptic seizures and anxiety crisis. J. Control. Release. 2019;295:187-200.
Not in our library10.1016/j.jconrel.2018.12.049 (opens in a new tab)
120.
Iqbal R., Ahmed S., Jain G.K., Vohora D. Design and development of letrozole nanoemulsion: A comparative evaluation of brain targeted nanoemulsion with free letrozole against status epilepticus and neurodegeneration in mice. Int. J. Pharm. 2019;565:20-32.
Not in our library10.1016/j.ijpharm.2019.04.076 (opens in a new tab)
121.
Harden C., MacLusky N.J. Aromatase inhibitors as add-on treatment for men with epilepsy. Expert Rev. Neurother. 2005;5:123-127.
Not in our library10.1586/14737175.5.1.123 (opens in a new tab)
122.
Iqbal R., Jain G.K., Siraj F., Vohora D. Aromatase inhibition by letrozole attenuates kainic acid-induced seizures but not neurotoxicity in mice. Epilepsy Res. 2018;143:60-69.
Not in our library10.1016/j.eplepsyres.2018.04.004 (opens in a new tab)
123.
Elieh-Ali-Komi D., Hamblin M.R. Chitin and Chitosan: Production and Application of Versatile Biomedical Nanomaterials. Int. J. Adv. Res. 2016;4:411-427.
Not in our library
124.
Nurunnabi M., Revuri V., Huh K.M., Lee Y.-k., Andronescu E., Grumezescu A.M. Chapter 14—Polysaccharide based nano/microformulation: An effective and versatile oral drug delivery system. Nanostructures for Oral Medicine. 2017;409-433.
Not in our library
125.
England R.J., Homer J.J., Knight L.C., Ell S.R. Nasal pH measurement: A reliable and repeatable parameter. Clin. Otolaryngol. Allied Sci. 1999;24:67-68.
Not in our library10.1046/j.1365-2273.1999.00223.x (opens in a new tab)
126.
Deli M.A. Potential use of tight junction modulators to reversibly open membranous barriers and improve drug delivery. Biochim. Biophys. Acta. 2009;1788:892-910.
Not in our library10.1016/j.bbamem.2008.09.016 (opens in a new tab)
127.
Smith J.M., Dornish M., Wood E.J. Involvement of protein kinase C in chitosan glutamate-mediated tight junction disruption. Biomaterials. 2005;26:3269-3276.
Not in our library10.1016/j.biomaterials.2004.06.020 (opens in a new tab)
128.
Gonçalves C., Ferreira N., Lourenço L. Production of Low Molecular Weight Chitosan and Chitooligosaccharides (COS): A Review. Polymers. 2021;13:2466.
Not in our library10.3390/polym13152466 (opens in a new tab)
129.
Cardia M.C., Carta A.R., Caboni P., Maccioni A.M., Erbì S., Boi L., Meloni M.C., Lai F., Sinico C. Trimethyl Chitosan Hydrogel Nanoparticles for Progesterone Delivery in Neurodegenerative Disorders. Pharmaceutics. 2019;11:657.
Not in our library10.3390/pharmaceutics11120657 (opens in a new tab)
130.
Kumar M., Pandey R.S., Patra K.C., Jain S.K., Soni M.L., Dangi J.S., Madan J. Evaluation of neuropeptide loaded trimethyl chitosan nanoparticles for nose to brain delivery. Int. J. Biol. Macromol. 2013;61:189-195.
Not in our library10.1016/j.ijbiomac.2013.06.041 (opens in a new tab)
131.
Singh D., Rashid M., Hallan S.S., Mehra N.K., Prakash A., Mishra N. Pharmacological evaluation of nasal delivery of selegiline hydrochloride-loaded thiolated chitosan nanoparticles for the treatment of depression. Artif. Cells Nanomed. Biotechnol. 2016;44:865-877.
Not in our library10.3109/21691401.2014.998824 (opens in a new tab)
132.
Patel D., Naik S., Chuttani K., Mathur R., Mishra A.K., Misra A. Intranasal delivery of cyclobenzaprine hydrochloride-loaded thiolated chitosan nanoparticles for pain relief. J. Drug Target. 2013;21:759-769.
Not in our library10.3109/1061186x.2013.818676 (opens in a new tab)
133.
Tønnesen H.H., Karlsen J. Alginate in drug delivery systems. Drug Dev. Ind. Pharm. 2002;28:621-630.
Not in our library10.1081/ddc-120003853 (opens in a new tab)
134.
Haque S., Md S., Sahni J.K., Ali J., Baboota S. Development and evaluation of brain targeted intranasal alginate nanoparticles for treatment of depression. J. Psychiatr. Res. 2014;48:1-12.
Not in our library10.1016/j.jpsychires.2013.10.011 (opens in a new tab)
135.
Wang Z., Xiong G., Tsang W.C., Schätzlein A.G., Uchegbu I.F. Nose-to-Brain Delivery. J. Pharmacol. Exp. Ther. 2019;370:593-601.
Not in our library10.1124/jpet.119.258152 (opens in a new tab)
136.
Ong W.Y., Shalini S.M., Costantino L. Nose-to-brain drug delivery by nanoparticles in the treatment of neurological disorders. Curr. Med. Chem. 2014;21:4247-4256.
Not in our library10.2174/0929867321666140716103130 (opens in a new tab)
137.
McCall R.L., Sirianni R.W. PLGA nanoparticles formed by single- or double-emulsion with vitamin E-TPGS. J. Vis. Exp. 2013;82:1-8.
Not in our library10.3791/51015 (opens in a new tab)
138.
Suk J.S., Xu Q., Kim N., Hanes J., Ensign L.M. PEGylation as a strategy for improving nanoparticle-based drug and gene delivery. Adv. Drug Deliv. Rev. 2016;99:28-51.
Not in our library10.1016/j.addr.2015.09.012 (opens in a new tab)
139.
Muntimadugu E., Dhommati R., Jain A., Challa V.G., Shaheen M., Khan W. Intranasal delivery of nanoparticle encapsulated tarenflurbil: A potential brain targeting strategy for Alzheimer’s disease. Eur. J. Pharm. Sci. 2016;92:224-234.
Not in our library10.1016/j.ejps.2016.05.012 (opens in a new tab)
140.
Mistry A., Glud S.Z., Kjems J., Randel J., Howard K.A., Stolnik S., Illum L. Effect of physicochemical properties on intranasal nanoparticle transit into murine olfactory epithelium. J. Drug Target. 2009;17:543-552.
Not in our library10.1080/10611860903055470 (opens in a new tab)
141.
Ahmad E., Feng Y., Qi J., Fan W., Ma Y., He H., Xia F., Dong X., Zhao W., Lu Y., et al. Evidence of nose-to-brain delivery of nanoemulsions: Cargoes but not vehicles. Nanoscale. 2017;9:1174-1183.
Not in our library10.1039/c6nr07581a (opens in a new tab)
142.
Law S.L., Huang K.J., Chou H.Y. Preparation of desmopressin-containing liposomes for intranasal delivery. J. Control. Release. 2001;70:375-382.
Not in our library10.1016/s0168-3659(00)00369-2 (opens in a new tab)
143.
Gabal Y.M., Kamel A.O., Sammour O.A., Elshafeey A.H. Effect of surface charge on the brain delivery of nanostructured lipid carriers in situ gels via the nasal route. Int. J. Pharm. 2014;473:442-457.
Not in our library10.1016/j.ijpharm.2014.07.025 (opens in a new tab)
144.
Bonaccorso A., Musumeci T., Serapide M.F., Pellitteri R., Uchegbu I.F., Puglisi G. Nose to brain delivery in rats: Effect of surface charge of rhodamine B labeled nanocarriers on brain subregion localization. Colloids Surf. B Biointerfaces. 2017;154:297-306.
Not in our library10.1016/j.colsurfb.2017.03.035 (opens in a new tab)
145.
Sosnik A., das Neves J., Sarmento B. Mucoadhesive polymers in the design of nano-drug delivery systems for administration by non-parenteral routes: A review. Prog. Polym. Sci. 2014;39:2030-2075.
Not in our library10.1016/j.progpolymsci.2014.07.010 (opens in a new tab)
146.
Kanazawa T., Kaneko M., Niide T., Akiyama F., Kakizaki S., Ibaraki H., Shiraishi S., Takashima Y., Suzuki T., Seta Y. Enhancement of nose-to-brain delivery of hydrophilic macromolecules with stearate- or polyethylene glycol-modified arginine-rich peptide. Int. J. Pharm. 2017;530:195-200.
Not in our library10.1016/j.ijpharm.2017.07.077 (opens in a new tab)
147.
Wells B.G., DiPiro J.T., Schwinghammer T.L., DiPiro C.V. Epilepsy. Pharmacotherapy Quick Guide. 2017.
Not in our library
148.
Milligan T.A. Epilepsy: A Clinical Overview. Am. J. Med. 2021;134:840-847.
Not in our library10.1016/j.amjmed.2021.01.038 (opens in a new tab)
149.
Vaughan K.A., Lopez Ramos C., Buch V.P., Mekary R.A., Amundson J.R., Shah M., Rattani A., Dewan M.C., Park K.B. An estimation of global volume of surgically treatable epilepsy based on a systematic review and meta-analysis of epilepsy. J. Neurosurg. 2018;130:1-15.
Not in our library10.3171/2018.3.jns171722 (opens in a new tab)
150.
Falco-Walter J.J., Scheffer I.E., Fisher R.S. The new definition and classification of seizures and epilepsy. Epilepsy Res. 2018;139:73-79.
Not in our library10.1016/j.eplepsyres.2017.11.015 (opens in a new tab)
151.
Engel J. Mechanisms of Neuronal Excitation and Synchronization. Seizures and Epilepsy. 2013.
Not in our library
152.
Trinka E., Cock H., Hesdorffer D., Rossetti A.O., Scheffer I.E., Shinnar S., Shorvon S., Lowenstein D.H. A definition and classification of status epilepticus—Report of the ILAE Task Force on Classification of Status Epilepticus. Epilepsia. 2015;56:1515-1523.
Not in our library10.1111/epi.13121 (opens in a new tab)
153.
Antiepileptic Drug Interactions - Principles and Clinical Implications · 2010
No notice
154.
Musumeci T., Bonaccorso A., Puglisi G. Epilepsy Disease and Nose-to-Brain Delivery of Polymeric Nanoparticles: An Overview. Pharmaceutics. 2019;11:118.
Not in our library10.3390/pharmaceutics11030118 (opens in a new tab)
155.
Samia O., Hanan R., Kamal E.T. Carbamazepine mucoadhesive nanoemulgel (MNEG) as brain targeting delivery system via the olfactory mucosa. Drug Deliv. 2012;19:58-67.
Not in our library10.3109/10717544.2011.644349 (opens in a new tab)
156.
Sharma D., Sharma R.K., Sharma N., Gabrani R., Sharma S.K., Ali J., Dang S. Nose-To-Brain Delivery of PLGA-Diazepam Nanoparticles. AAPS PharmSciTech. 2015;16:1108-1121.
Not in our library10.1208/s12249-015-0294-0 (opens in a new tab)
157.
Musumeci T., Serapide M.F., Pellitteri R., Dalpiaz A., Ferraro L., Dal Magro R., Bonaccorso A., Carbone C., Veiga F., Sancini G., et al. Oxcarbazepine free or loaded PLGA nanoparticles as effective intranasal approach to control epileptic seizures in rodents. Eur. J. Pharm. Biopharm. 2018;133:309-320.
Not in our library10.1016/j.ejpb.2018.11.002 (opens in a new tab)
158.
El-Zaafarany G.M., Soliman M.E., Mansour S., Awad G.A. Identifying lipidic emulsomes for improved oxcarbazepine brain targeting: In vitro and rat in vivo studies. Int. J. Pharm. 2016;503:127-140.
Not in our library10.1016/j.ijpharm.2016.02.038 (opens in a new tab)
159.
Ahmad N., Ahmad R., Alam M.A., Ahmad F.J., Amir M. Impact of ultrasonication techniques on the preparation of novel Amiloride-nanoemulsion used for intranasal delivery in the treatment of epilepsy. Artif. Cells Nanomed. Biotechnol. 2018;46:S192-S207.
Not in our library10.1080/21691401.2018.1489826 (opens in a new tab)
160.
Kubek M.J., Domb A.J., Veronesi M.C. Attenuation of kindled seizures by intranasal delivery of neuropeptide-loaded nanoparticles. Neurotherapeutics. 2009;6:359-371.
Not in our library10.1016/j.nurt.2009.02.001 (opens in a new tab)
161.
Sharma D., Maheshwari D., Philip G., Rana R., Bhatia S., Singh M., Gabrani R., Sharma S.K., Ali J., Sharma R.K., et al. Formulation and optimization of polymeric nanoparticles for intranasal delivery of lorazepam using Box-Behnken design: In vitro and in vivo evaluation. Biomed. Res. Int. 2014;2014:156010.
Not in our library10.1155/2014/156010 (opens in a new tab)
162.
Praveen A., Aqil M., Imam S.S., Ahad A., Moolakkadath T., Ahmad F.J. Lamotrigine encapsulated intra-nasal nanoliposome formulation for epilepsy treatment: Formulation design, characterization and nasal toxicity study. Colloids Surf. B Biointerfaces. 2019;174:553-562.
Not in our library10.1016/j.colsurfb.2018.11.025 (opens in a new tab)
163.
Aithal G.C., Narayan R., Nayak U.Y. Nanoemulgel: A Promising Phase in Drug Delivery. Curr. Pharm. Des. 2020;26:279-291.
Not in our library10.2174/1381612826666191226100241 (opens in a new tab)
164.
Newell B.D., Moinfar M., Mancini A.J., Nopper A.J. Retrospective analysis of 32 pediatric patients with anticonvulsant hypersensitivity syndrome (ACHSS). Pediatr. Dermatol. 2009;26:536-546.
Not in our library10.1111/j.1525-1470.2009.00870.x (opens in a new tab)
165.
Mehta M., Shah J., Khakhkhar T., Shah R., Hemavathi K.G. Anticonvulsant hypersensitivity syndrome associated with carbamazepine administration: Case series. J. Pharmacol. Pharmacother. 2014;5:59-62.
Not in our library10.4103/0976-500x.124428 (opens in a new tab)
166.
Lo Y.M., Argin-Soysal S., Hsu C.-H., Yang S.-T. Chapter 22—Bioconversion of Whey Lactose into Microbial Exopolysaccharides. Bioprocessing for Value-Added Products from Renewable Resources. 2007;559-583.
Not in our library
167.
Dhaliwal J.S., Rosani A., Saadabadi A. Diazepam. 2020.
Not in our library
168.
Abou-Khalil B.W. Oxcarbazepine and carbamazepine: Expected and unexpected differences and similarities. Epilepsy Curr. 2007;7:74-76.
Not in our library10.1111/j.1535-7511.2007.00176.x (opens in a new tab)
169.
Ucisik M.H., Sleytr U.B., Schuster B. Emulsomes meet S-layer proteins: An emerging targeted drug delivery system. Curr. Pharm. Biotechnol. 2015;16:392-405.
Not in our library10.2174/138920101604150218112656 (opens in a new tab)
170.
Neugroschl J., Wang S. Alzheimer’s disease: Diagnosis and treatment across the spectrum of disease severity. Mt. Sinai J. Med. 2011;78:596-612.
Not in our library10.1002/msj.20279 (opens in a new tab)
171.
Mebane-Sims I. 2020 Alzheimer’s disease facts and figures. Alzheimers Dement. 2020;16:391-460.
Not in our library10.1002/alz.12068 (opens in a new tab)
172.
Hebert L.E., Weuve J., Scherr P.A., Evans D.A. Alzheimer disease in the United States (2010-2050) estimated using the 2010 census. Neurology. 2013;80:1778-1783.
Not in our library10.1212/wnl.0b013e31828726f5 (opens in a new tab)
173.
Brunnström H.R., Englund E.M. Cause of death in patients with dementia disorders. Eur. J. Neurol. 2009;16:488-492.
Not in our library10.1111/j.1468-1331.2008.02503.x (opens in a new tab)
174.
Williamson J., Goldman J., Marder K.S. Genetic aspects of Alzheimer disease. Neurologist. 2009;15:80-86.
Not in our library10.1097/nrl.0b013e318187e76b (opens in a new tab)
175.
Bloom G.S. Amyloid-β and tau: The trigger and bullet in Alzheimer disease pathogenesis. JAMA Neurol. 2014;71:505-508.
Not in our library10.1001/jamaneurol.2013.5847 (opens in a new tab)
176.
Peron E.P., Zimmerman K.M., Crouse E.L., Slattum P.W., Hobgood S.E., DiPiro J.T., Yee G.C., Posey L., Haines S.T., Nolin T.D., Ellingrod V. Alzheimer Disease. Pharmacotherapy: A Pathophysiologic Approach, 11e. 2020.
Not in our library
177.
Sadowsky C.H., Galvin J.E. Guidelines for the management of cognitive and behavioral problems in dementia. J. Am. Board Fam. Med. 2012;25:350-366.
Not in our library10.3122/jabfm.2012.03.100183 (opens in a new tab)
178.
Md S., Ali M., Ali R., Bhatnagar A., Baboota S., Ali J. Donepezil nanosuspension intended for nose to brain targeting: In vitro and in vivo safety evaluation. Int. J. Biol. Macromol. 2014;67:418-425.
Not in our library10.1016/j.ijbiomac.2014.03.022 (opens in a new tab)
179.
Md S., Ali M., Baboota S., Sahni J.K., Bhatnagar A., Ali J. Preparation, characterization, in vivo biodistribution and pharmacokinetic studies of donepezil-loaded PLGA nanoparticles for brain targeting. Drug Dev. Ind. Pharm. 2014;40:278-287.
Not in our library10.3109/03639045.2012.758130 (opens in a new tab)
180.
Singh S.K., Mishra D.N. Nose to Brain Delivery of Galantamine Loaded Nanoparticles: In-vivo Pharmacodynamic and Biochemical Study in Mice. Curr. Drug Deliv. 2019;16:51-58.
Not in our library10.2174/1567201815666181004094707 (opens in a new tab)
181.
Li W., Zhou Y., Zhao N., Hao B., Wang X., Kong P. Pharmacokinetic behavior and efficiency of acetylcholinesterase inhibition in rat brain after intranasal administration of galanthamine hydrobromide loaded flexible liposomes. Environ. Toxicol. Pharmacol. 2012;34:272-279.
Not in our library10.1016/j.etap.2012.04.012 (opens in a new tab)
182.
Misra S., Chopra K., Sinha V.R., Medhi B. Galantamine-loaded solid-lipid nanoparticles for enhanced brain delivery: Preparation, characterization, in vitro and in vivo evaluations. Drug Deliv. 2016;23:1434-1443.
Not in our library10.3109/10717544.2015.1089956 (opens in a new tab)
183.
Kaur A., Nigam K., Srivastava S., Tyagi A., Dang S. Memantine nanoemulsion: A new approach to treat Alzheimer’s disease. J. Microencapsul. 2020;37:355-365.
Not in our library10.1080/02652048.2020.1756971 (opens in a new tab)
184.
Jojo G.M., Kuppusamy G., De A., Karri V. Formulation and optimization of intranasal nanolipid carriers of pioglitazone for the repurposing in Alzheimer’s disease using Box-Behnken design. Drug Dev. Ind. Pharm. 2019;45:1061-1072.
Not in our library10.1080/03639045.2019.1593439 (opens in a new tab)
185.
Meng Q., Wang A., Hua H., Jiang Y., Wang Y., Mu H., Wu Z., Sun K. Intranasal delivery of Huperzine A to the brain using lactoferrin-conjugated N-trimethylated chitosan surface-modified PLGA nanoparticles for treatment of Alzheimer’s disease. Int. J. Nanomedicine. 2018;13:705-718.
Not in our library10.2147/ijn.s151474 (opens in a new tab)
186.
Fazil M., Md S., Haque S., Kumar M., Baboota S., Sahni J.K., Ali J. Development and evaluation of rivastigmine loaded chitosan nanoparticles for brain targeting. Eur. J. Pharm. Sci. 2012;47:6-15.
Not in our library10.1016/j.ejps.2012.04.013 (opens in a new tab)
187.
Yang Z.Z., Zhang Y.Q., Wang Z.Z., Wu K., Lou J.N., Qi X.R. Enhanced brain distribution and pharmacodynamics of rivastigmine by liposomes following intranasal administration. Int. J. Pharm. 2013;452:344-354.
Not in our library10.1016/j.ijpharm.2013.05.009 (opens in a new tab)
188.
Rassu G., Soddu E., Posadino A.M., Pintus G., Sarmento B., Giunchedi P., Gavini E. Nose-to-brain delivery of BACE1 siRNA loaded in solid lipid nanoparticles for Alzheimer’s therapy. Colloids Surf. B Biointerfaces. 2017;152:296-301.
Not in our library10.1016/j.colsurfb.2017.01.031 (opens in a new tab)
189.
Wong L.R., Ho P.C. Role of serum albumin as a nanoparticulate carrier for nose-to-brain delivery of R-flurbiprofen: Implications for the treatment of Alzheimer’s disease. J. Pharm. Pharmacol. 2018;70:59-69.
Not in our library10.1111/jphp.12836 (opens in a new tab)
190.
Galimberti D., Scarpini E. Pioglitazone for the treatment of Alzheimer’s disease. Expert Opin. Investig. Drugs. 2017;26:97-101.
Not in our library10.1080/13543784.2017.1265504 (opens in a new tab)
191.
Hu S.H., Jiang T., Yang S.S., Yang Y. Pioglitazone ameliorates intracerebral insulin resistance and tau-protein hyperphosphorylation in rats with type 2 diabetes. Exp. Clin. Endocrinol. Diabetes. 2013;121:220-224.
Not in our library10.1055/s-0032-1333277 (opens in a new tab)
192.
Seok H., Lee M., Shin E., Yun M.R., Lee Y.-h., Moon J.H., Kim E., Lee P.H., Lee B.-W., Kang E.S., et al. Low-dose pioglitazone can ameliorate learning and memory impairment in a mouse model of dementia by increasing LRP1 expression in the hippocampus. Sci. Rep. 2019;9:4414.
Not in our library10.1038/s41598-019-40736-x (opens in a new tab)
193.
Alam F., Islam M.A., Mohamed M., Ahmad I., Kamal M.A., Donnelly R., Idris I., Gan S.H. Efficacy and Safety of Pioglitazone Monotherapy in Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomised Controlled Trials. Sci. Rep. 2019;9:5389.
Not in our library10.1038/s41598-019-41854-2 (opens in a new tab)
194.
Zhang L., Song Y., Lu C., Zhang J., Yuan J., Wang T., Fu F. The effects of huperzine A on gastrointestinal acetylcholinesterase activity and motility after single and multiple dosing in mice. Exp. Ther. Med. 2013;5:793-796.
Not in our library10.3892/etm.2013.883 (opens in a new tab)
195.
Orozco J.L., Valderrama-Chaparro J.A., Pinilla-Monsalve G.D., Molina-Echeverry M.I., Pérez Castaño A.M., Ariza-Araújo Y., Prada S.I., Takeuchi Y. Parkinson’s disease prevalence, age distribution and staging in Colombia. Neurol. Int. 2020;12:8401.
Not in our library10.4081/ni.2020.8401 (opens in a new tab)
196.
Chen J.J., Dashtipour K., DiPiro J.T., Yee G.C., Posey L., Haines S.T., Nolin T.D., Ellingrod V. Parkinson Disease. Pharmacotherapy: A Pathophysiologic Approach, 11e. 2020.
Not in our library
197.
Fearnley J.M., Lees A.J. Ageing and Parkinson’s disease: Substantia nigra regional selectivity. Brain. 1991;114:2283-2301.
Not in our library10.1093/brain/114.5.2283 (opens in a new tab)
198.
Wakabayashi K., Tanji K., Mori F., Takahashi H. The Lewy body in Parkinson’s disease: Molecules implicated in the formation and degradation of alpha-synuclein aggregates. Neuropathology. 2007;27:494-506.
Not in our library10.1111/j.1440-1789.2007.00803.x (opens in a new tab)
199.
Jankovic J., Aguilar L.G. Current approaches to the treatment of Parkinson’s disease. Neuropsychiatr. Dis. Treat. 2008;4:743-757.
Not in our library10.2147/ndt.s2006 (opens in a new tab)
200.
Mittal D., Md S., Hasan Q., Fazil M., Ali A., Baboota S., Ali J. Brain targeted nanoparticulate drug delivery system of rasagiline via intranasal route. Drug Deliv. 2016;23:130-139.
Not in our library10.3109/10717544.2014.907372 (opens in a new tab)
201.
Brain-targeted intranasal delivery of dopamine with borneol and lactoferrin co-modified nanoparticles for treating Parkinson’s disease · 2019
No notice
202.
Md S., Khan R.A., Mustafa G., Chuttani K., Baboota S., Sahni J.K., Ali J. Bromocriptine loaded chitosan nanoparticles intended for direct nose to brain delivery: Pharmacodynamic, pharmacokinetic and scintigraphy study in mice model. Eur. J. Pharm. Sci. 2013;48:393-405.
Not in our library10.1016/j.ejps.2012.12.007 (opens in a new tab)
203.
Bhattamisra S.K., Shak A.T., Xi L.W., Safian N.H., Choudhury H., Lim W.M., Shahzad N., Alhakamy N.A., Anwer M.K., Radhakrishnan A.K., et al. Nose to brain delivery of rotigotine loaded chitosan nanoparticles in human SH-SY5Y neuroblastoma cells and animal model of Parkinson’s disease. Int. J. Pharm. 2020;579:119148.
Not in our library10.1016/j.ijpharm.2020.119148 (opens in a new tab)
204.
Bi C., Wang A., Chu Y., Liu S., Mu H., Liu W., Wu Z., Sun K., Li Y. Intranasal delivery of rotigotine to the brain with lactoferrin-modified PEG-PLGA nanoparticles for Parkinson’s disease treatment. Int. J. Nanomedicine. 2016;11:6547-6559.
Not in our library10.2147/ijn.s120939 (opens in a new tab)
205.
Mishra N., Sharma S., Deshmukh R., Kumar A., Sharma R. Development and Characterization of Nasal Delivery of Selegiline Hydrochloride Loaded Nanolipid Carriers for the Management of Parkinson’s Disease. Cent. Nerv. Syst. Agents Med. Chem. 2019;19:46-56.
Not in our library10.2174/1871524919666181126124846 (opens in a new tab)
206.
Kumar S., Dang S., Nigam K., Ali J., Baboota S. Selegiline Nanoformulation in Attenuation of Oxidative Stress and Upregulation of Dopamine in the Brain for the Treatment of Parkinson’s Disease. Rejuvenation Res. 2018;21:464-476.
Not in our library10.1089/rej.2017.2035 (opens in a new tab)
207.
De Oliveira Junior E.R., Truzzi E., Ferraro L., Fogagnolo M., Pavan B., Beggiato S., Rustichelli C., Maretti E., Lima E.M., Leo E., et al. Nasal administration of nanoencapsulated geraniol/ursodeoxycholic acid conjugate: Towards a new approach for the management of Parkinson’s disease. J. Control. Release. 2020;321:540-552.
Not in our library10.1016/j.jconrel.2020.02.033 (opens in a new tab)
208.
Pardeshi C.V., Rajput P.V., Belgamwar V.S., Tekade A.R., Surana S.J. Novel surface modified solid lipid nanoparticles as intranasal carriers for ropinirole hydrochloride: Application of factorial design approach. Drug Deliv. 2013;20:47-56.
Not in our library10.3109/10717544.2012.752421 (opens in a new tab)
209.
Jafarieh O., Md S., Ali M., Baboota S., Sahni J.K., Kumari B., Bhatnagar A., Ali J. Design, characterization, and evaluation of intranasal delivery of ropinirole-loaded mucoadhesive nanoparticles for brain targeting. Drug Dev. Ind. Pharm. 2015;41:1674-1681.
Not in our library10.3109/03639045.2014.991400 (opens in a new tab)
210.
Patil G.B., Surana S.J. Fabrication and statistical optimization of surface engineered PLGA nanoparticles for naso-brain delivery of ropinirole hydrochloride: In-vitro-ex-vivo studies. J. Biomater. Sci. Polym. Ed. 2013;24:1740-1756.
Not in our library10.1080/09205063.2013.798880 (opens in a new tab)
211.
Raj R., Wairkar S., Sridhar V., Gaud R. Pramipexole dihydrochloride loaded chitosan nanoparticles for nose to brain delivery: Development, characterization and in vivo anti-Parkinson activity. Int. J. Biol. Macromol. 2018;109:27-35.
Not in our library10.1016/j.ijbiomac.2017.12.056 (opens in a new tab)
212.
Gaba B., Khan T., Haider M.F., Alam T., Baboota S., Parvez S., Ali J. Vitamin E Loaded Naringenin Nanoemulsion via Intranasal Delivery for the Management of Oxidative Stress in a 6-OHDA Parkinson’s Disease Model. Biomed. Res. Int. 2019;2019:2382563.
Not in our library10.1155/2019/2382563 (opens in a new tab)
213.
Wen Z., Yan Z., Hu K., Pang Z., Cheng X., Guo L., Zhang Q., Jiang X., Fang L., Lai R. Odorranalectin-conjugated nanoparticles: Preparation, brain delivery and pharmacodynamic study on Parkinson’s disease following intranasal administration. J. Control. Release. 2011;151:131-138.
Not in our library10.1016/j.jconrel.2011.02.022 (opens in a new tab)
214.
Fernández M., Negro S., Slowing K., Fernández-Carballido A., Barcia E. An effective novel delivery strategy of rasagiline for Parkinson’s disease. Int. J. Pharm. 2011;419:271-280.
Not in our library10.1016/j.ijpharm.2011.07.029 (opens in a new tab)
215.
Gavini E., Rassu G., Ferraro L., Generosi A., Rau J.V., Brunetti A., Giunchedi P., Dalpiaz A. Influence of chitosan glutamate on the in vivo intranasal absorption of rokitamycin from microspheres. J. Pharm. Sci. 2011;100:1488-1502.
Not in our library10.1002/jps.22382 (opens in a new tab)
216.
Qi H.P., Gao X.C., Zhang L.Q., Wei S.Q., Bi S., Yang Z.C., Cui H. In vitro evaluation of enhancing effect of borneol on transcorneal permeation of compounds with different hydrophilicities and molecular sizes. Eur. J. Pharmacol. 2013;705:20-25.
Not in our library10.1016/j.ejphar.2013.02.031 (opens in a new tab)
217.
Vautier S., Lacomblez L., Chacun H., Picard V., Gimenez F., Farinotti R., Fernandez C. Interactions between the dopamine agonist, bromocriptine and the efflux protein, P-glycoprotein at the blood-brain barrier in the mouse. Eur. J. Pharm. Sci. 2006;27:167-174.
Not in our library10.1016/j.ejps.2005.09.009 (opens in a new tab)
218.
Chaudhuri K.R. Crystallisation within transdermal rotigotine patch: Is there cause for concern? Expert Opin. Drug Deliv. 2008;5:1169-1171.
Not in our library10.1517/17425240802500870 (opens in a new tab)
219.
Modeling Parkinson’s Disease With the Alpha-Synuclein Protein · 2020
No notice
220.
Stroke: a global response is needed · 2016
No notice
221.
Virani S.S., Alonso A., Aparicio H.J., Benjamin E.J., Bittencourt M.S., Callaway C.W., Carson A.P., Chamberlain A.M., Cheng S., Delling F.N., et al. Heart Disease and Stroke Statistics-2021 Update: A Report From the American Heart Association. Circulation. 2021;143:e254-e743.
Not in our library10.1161/cir.0000000000000950 (opens in a new tab)
222.
Xing C., Arai K., Lo E.H., Hommel M. Pathophysiologic cascades in ischemic stroke. Int. J. Stroke. 2012;7:378-385.
Not in our library10.1111/j.1747-4949.2012.00839.x (opens in a new tab)
223.
Powers W.J., Rabinstein A.A., Ackerson T., Adeoye O.M., Bambakidis N.C., Becker K., Biller J., Brown M., Demaerschalk B.M., Hoh B., et al. Guidelines for the Early Management of Patients With Acute Ischemic Stroke: 2019 Update to the 2018 Guidelines for the Early Management of Acute Ischemic Stroke: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association. Stroke. 2019;50:e344-e418.
Not in our library10.1161/str.0000000000000211 (opens in a new tab)
224.
Hemphill J.C., Greenberg S.M., Anderson C.S., Becker K., Bendok B.R., Cushman M., Fung G.L., Goldstein J.N., Macdonald R.L., Mitchell P.H., et al. Guidelines for the Management of Spontaneous Intracerebral Hemorrhage: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association. Stroke. 2015;46:2032-2060.
Not in our library10.1161/str.0000000000000069 (opens in a new tab)
225.
Xiao X.Y., Zhu Y.X., Bu J.Y., Li G.W., Zhou J.H., Zhou S.P. Evaluation of Neuroprotective Effect of Thymoquinone Nanoformulation in the Rodent Cerebral Ischemia-Reperfusion Model. Biomed. Res. Int. 2016;2016:2571060.
Not in our library10.1155/2016/2571060 (opens in a new tab)
226.
Li R., Huang Y., Chen L., Zhou H., Zhang M., Chang L., Shen H., Zhou M., Su P., Zhu D. Targeted delivery of intranasally administered nanoparticles-mediated neuroprotective peptide NR2B9c to brain and neuron for treatment of ischemic stroke. Nanomedicine. 2019;18:380-390.
Not in our library10.1016/j.nano.2018.10.013 (opens in a new tab)
227.
Ahmad N., Ahmad I., Umar S., Iqbal Z., Samim M., Ahmad F.J. PNIPAM nanoparticles for targeted and enhanced nose-to-brain delivery of curcuminoids: UPLC/ESI-Q-ToF-MS/MS-based pharmacokinetics and pharmacodynamic evaluation in cerebral ischemia model. Drug Deliv. 2016;23:2095-2114.
Not in our library10.3109/10717544.2014.941076 (opens in a new tab)
228.
Therapeutic Potential and Pharmaceutical Development of Thymoquinone: A Multitargeted Molecule of Natural Origin · 2017
No notice
229.
Aarts M., Liu Y., Liu L., Besshoh S., Arundine M., Gurd J.W., Wang Y.T., Salter M.W., Tymianski M. Treatment of ischemic brain damage by perturbing NMDA receptor- PSD-95 protein interactions. Science. 2002;298:846-850.
Not in our library10.1126/science.1072873 (opens in a new tab)
230.
Baker H., Spencer R.F. Transneuronal transport of peroxidase-conjugated wheat germ agglutinin (WGA-HRP) from the olfactory epithelium to the brain of the adult rat. Exp. Brain Res. 1986;63:461-473.
Not in our library10.1007/bf00237470 (opens in a new tab)
231.
McGrath J., Saha S., Chant D., Welham J. Schizophrenia: A concise overview of incidence, prevalence, and mortality. Epidemiol. Rev. 2008;30:67-76.
Not in our library10.1093/epirev/mxn001 (opens in a new tab)
232.
Crismon M., Smith T., Buckley P.F., DiPiro J.T., Yee G.C., Posey L., Haines S.T., Nolin T.D., Ellingrod V. Schizophrenia. Pharmacotherapy: A Pathophysiologic Approach, 11e. 2020.
Not in our library
233.
Chokhawala K., Stevens L. Antipsychotic Medications. StatPearls. 2021.
Not in our library
234.
De Araújo A.N., de Sena E.P., de Oliveira I.R., Juruena M.F. Antipsychotic agents: Efficacy and safety in schizophrenia. Drug Healthc. Patient Saf. 2012;4:173-180.
Not in our library10.2147/dhps.s37429 (opens in a new tab)
235.
Maroney M. An update on current treatment strategies and emerging agents for the management of schizophrenia. Am. J. Manag. Care. 2020;26:S55-S61.
Not in our library10.37765/ajmc.2020.43012 (opens in a new tab)
236.
Tan M.S.A., Parekh H.S., Pandey P., Siskind D.J., Falconer J.R. Nose-to-brain delivery of antipsychotics using nanotechnology: A review. Expert Opin. Drug Deliv. 2020;17:839-853.
Not in our library10.1080/17425247.2020.1762563 (opens in a new tab)
237.
Shah B., Khunt D., Misra M., Padh H. Application of Box-Behnken design for optimization and development of quetiapine fumarate loaded chitosan nanoparticles for brain delivery via intranasal route*. Int. J. Biol. Macromol. 2016;89:206-218.
Not in our library10.1016/j.ijbiomac.2016.04.076 (opens in a new tab)
238.
Boche M., Pokharkar V. Quetiapine Nanoemulsion for Intranasal Drug Delivery: Evaluation of Brain-Targeting Efficiency. AAPS PharmSciTech. 2017;18:686-696.
Not in our library10.1208/s12249-016-0552-9 (opens in a new tab)
239.
Sawant K., Pandey A., Patel S. Aripiprazole loaded poly(caprolactone) nanoparticles: Optimization and in vivo pharmacokinetics. Mater. Sci. Eng. C Mater. Biol. Appl. 2016;66:230-243.
Not in our library10.1016/j.msec.2016.04.089 (opens in a new tab)
240.
Fonseca F.N., Betti A.H., Carvalho F.C., Gremião M.P., Dimer F.A., Guterres S.S., Tebaldi M.L., Rates S.M., Pohlmann A.R. Mucoadhesive Amphiphilic Methacrylic Copolymer-Functionalized Poly(ε-caprolactone) Nanocapsules for Nose-to-Brain Delivery of Olanzapine. J. Biomed. Nanotechnol. 2015;11:1472-1481.
Not in our library10.1166/jbn.2015.2078 (opens in a new tab)
241.
Seju U., Kumar A., Sawant K.K. Development and evaluation of olanzapine-loaded PLGA nanoparticles for nose-to-brain delivery: In vitro and in vivo studies. Acta Biomater. 2011;7:4169-4176.
Not in our library10.1016/j.actbio.2011.07.025 (opens in a new tab)
242.
Kumar M., Misra A., Babbar A.K., Mishra A.K., Mishra P., Pathak K. Intranasal nanoemulsion based brain targeting drug delivery system of risperidone. Int. J. Pharm. 2008;358:285-291.
Not in our library10.1016/j.ijpharm.2008.03.029 (opens in a new tab)
243.
Bahadur S., Pathak K. Buffered nanoemulsion for nose to brain delivery of ziprasidone hydrochloride: Preformulation and pharmacodynamic evaluation. Curr. Drug Deliv. 2012;9:596-607.
Not in our library10.2174/156720112803529792 (opens in a new tab)
244.
Horacek J., Bubenikova-Valesova V., Kopecek M., Palenicek T., Dockery C., Mohr P., Höschl C. Mechanism of action of atypical antipsychotic drugs and the neurobiology of schizophrenia. CNS Drugs. 2006;20:389-409.
Not in our library10.2165/00023210-200620050-00004 (opens in a new tab)
245.
Narala A., Veerabrahma K. Preparation, Characterization and Evaluation of Quetiapine Fumarate Solid Lipid Nanoparticles to Improve the Oral Bioavailability. J. Pharm. 2013;2013:265741.
Not in our library10.1155/2013/265741 (opens in a new tab)
246.
Emmert D., Campos C.R., Ward D., Lu P., Namanja H.A., Bohn K., Miller D.S., Sharom F.J., Chmielewski J., Hrycyna C.A. Reversible dimers of the atypical antipsychotic quetiapine inhibit p-glycoprotein-mediated efflux in vitro with increased binding affinity and in situ at the blood-brain barrier. ACS Chem. Neurosci. 2014;5:305-317.
Not in our library10.1021/cn4002329 (opens in a new tab)
247.
Silki, Sinha V.R. Enhancement of In Vivo Efficacy and Oral Bioavailability of Aripiprazole with Solid Lipid Nanoparticles. AAPS PharmSciTech. 2018;19:1264-1273.
Not in our library10.1208/s12249-017-0944-5 (opens in a new tab)
248.
Bassi A.K., Gough J.E., Zakikhani M., Downes S. The Chemical and Physical Properties of Poly(ε-caprolactone) Scaffolds Functionalised with Poly(vinyl phosphonic acid-co-acrylic acid). J. Tissue Eng. 2011;2011:615328.
Not in our library10.4061/2011/615328 (opens in a new tab)
249.
Reduced Prepulse Inhibition as a Biomarker of Schizophrenia · 2016
No notice
250.
Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017 · 2018
No notice
251.
Genetics Factors in Major Depression Disease · 2018
No notice
252.
VandenBerg A.M., DiPiro J.T., Yee G.C., Posey L.M., Haines S.T., Nolin T.D., Ellingrod V. Major Depressive Disorder. Pharmacotherapy: A Pathophysiologic Approach, 11e. 2020.
Not in our library
253.
Al-Harbi K.S. Treatment-resistant depression: Therapeutic trends, challenges, and future directions. Patient Prefer. Adherence. 2012;6:369-388.
Not in our library10.2147/ppa.s29716 (opens in a new tab)
254.
Demeule M., Régina A., Jodoin J., Laplante A., Dagenais C., Berthelet F., Moghrabi A., Béliveau R. Drug transport to the brain: Key roles for the efflux pump P-glycoprotein in the blood–brain barrier. Vasc. Pharmacol. 2002;38:339-348.
Not in our library10.1016/s1537-1891(02)00201-x (opens in a new tab)
255.
Vitorino C., Silva S., Bicker J., Falcão A., Fortuna A. Antidepressants and nose-to-brain delivery: Drivers, restraints, opportunities and challenges. Drug Discov. Today. 2019;24:1911-1923.
Not in our library10.1016/j.drudis.2019.06.001 (opens in a new tab)
256.
Haque S., Md S., Fazil M., Kumar M., Sahni J.K., Ali J., Baboota S. Venlafaxine loaded chitosan NPs for brain targeting: Pharmacokinetic and pharmacodynamic evaluation. Carbohydr. Polym. 2012;89:72-79.
Not in our library10.1016/j.carbpol.2012.02.051 (opens in a new tab)
257.
Tong G.F., Qin N., Sun L.W. Development and evaluation of Desvenlafaxine loaded PLGA-chitosan nanoparticles for brain delivery. Saudi Pharm. J. 2017;25:844-851.
Not in our library10.1016/j.jsps.2016.12.003 (opens in a new tab)
258.
Bari N.K., Fazil M., Hassan M.Q., Haider M.R., Gaba B., Narang J.K., Baboota S., Ali J. Brain delivery of buspirone hydrochloride chitosan nanoparticles for the treatment of general anxiety disorder. Int. J. Biol. Macromol. 2015;81:49-59.
Not in our library10.1016/j.ijbiomac.2015.07.041 (opens in a new tab)
259.
Fatouh A.M., Elshafeey A.H., Abdelbary A. Intranasal agomelatine solid lipid nanoparticles to enhance brain delivery: Formulation, optimization and in vivo pharmacokinetics. Drug Des. Devel. Ther. 2017;11:1815-1825.
Not in our library10.2147/dddt.s102500 (opens in a new tab)
260.
Stahl S.M., Grady M.M., Moret C., Briley M. SNRIs: Their pharmacology, clinical efficacy, and tolerability in comparison with other classes of antidepressants. CNS Spectr. 2005;10:732-747.
Not in our library10.1017/s1092852900019726 (opens in a new tab)
261.
Bronowska A., Chilmonczyk Z., Leś A., Edvardsen O., Ostensen R., Sylte I. Molecular dynamics of 5-HT1A and 5-HT2A serotonin receptors with methylated buspirone analogues. J. Comput. Aided. Mol. Des. 2001;15:1005-1023.
Not in our library10.1023/a:1014856107486 (opens in a new tab)
262.
Mahmood I., Sahajwalla C. Clinical pharmacokinetics and pharmacodynamics of buspirone, an anxiolytic drug. Clin. Pharmacokinet. 1999;36:277-287.
Not in our library10.2165/00003088-199936040-00003 (opens in a new tab)
263.
Javia A., Thakkar H. Intranasal delivery of tapentadol hydrochloride-loaded chitosan nanoparticles: Formulation, characterisation and its in vivo evaluation. J. Microencapsul. 2017;34:644-658.
Not in our library10.1080/02652048.2017.1375038 (opens in a new tab)
264.
Nigam K., Kaur A., Tyagi A., Manda K., Gabrani R., Dang S. Baclofen-Loaded Poly (D,L-Lactide-Co-Glycolic Acid) Nanoparticles for Neuropathic Pain Management: In Vitro and In Vivo Evaluation. Rejuvenation Res. 2019;22:235-245.
Not in our library10.1089/rej.2018.2119 (opens in a new tab)
265.
Gadhave D.G., Kokare C.R. Nanostructured lipid carriers engineered for intranasal delivery of teriflunomide in multiple sclerosis: Optimization and in vivo studies. Drug Dev. Ind. Pharm. 2019;45:839-851.
Not in our library10.1080/03639045.2019.1576724 (opens in a new tab)
266.
Bhatt R., Singh D., Prakash A., Mishra N. Development, characterization and nasal delivery of rosmarinic acid-loaded solid lipid nanoparticles for the effective management of Huntington’s disease. Drug Deliv. 2015;22:931-939.
Not in our library10.3109/10717544.2014.880860 (opens in a new tab)
267.
Jain K., Sood S., Gowthamarajan K. Optimization of artemether-loaded NLC for intranasal delivery using central composite design. Drug Deliv. 2015;22:940-954.
Not in our library10.3109/10717544.2014.885999 (opens in a new tab)
268.
Nigam K., Kaur A., Tyagi A., Nematullah M., Khan F., Gabrani R., Dang S. Nose-to-brain delivery of lamotrigine-loaded PLGA nanoparticles. Drug Deliv. Transl. Res. 2019;9:879-890.
Not in our library10.1007/s13346-019-00622-5 (opens in a new tab)
269.
Joshi A.S., Patel H.S., Belgamwar V.S., Agrawal A., Tekade A.R. Solid lipid nanoparticles of ondansetron HCl for intranasal delivery: Development, optimization and evaluation. J. Mater. Sci. Mater. Med. 2012;23:2163-2175.
Not in our library10.1007/s10856-012-4702-7 (opens in a new tab)
270.
Patil G.B., Surana S.J. Bio-fabrication and statistical optimization of polysorbate 80 coated chitosan nanoparticles of tapentadol hydrochloride for central antinociceptive effect: In vitro-in vivo studies. Artif. Cells Nanomed. Biotechnol. 2017;45:505-514.
Not in our library10.3109/21691401.2016.1163713 (opens in a new tab)
271.
Tapentadol hydrochloride: A novel analgesic · 2013
Not checked
272.
Ghanavatian S., Derian A. Baclofen. StatPearls. 2021.
Not in our library
273.
Peterson L.K., Fujinami R.S. Inflammation, demyelination, neurodegeneration and neuroprotection in the pathogenesis of multiple sclerosis. J. Neuroimmunol. 2007;184:37-44.
Not in our library10.1016/j.jneuroim.2006.11.015 (opens in a new tab)
274.
Tanasescu R., Evangelou N., Constantinescu C.S. Role of oral teriflunomide in the management of multiple sclerosis. Neuropsychiatr. Dis. Treat. 2013;9:539-553.
Not in our library10.2147/ndt.s31248 (opens in a new tab)
275.
Zheng Z., Diamond M.I. Huntington disease and the huntingtin protein. Prog. Mol. Biol. Transl. Sci. 2012;107:189-214.
Not in our library10.1016/b978-0-12-385883-2.00010-2 (opens in a new tab)
276.
Ghasemzadeh Rahbardar M., Hosseinzadeh H. Effects of rosmarinic acid on nervous system disorders: An updated review. Naunyn Schmiedeberg Arch. Pharmacol. 2020;393:1779-1795.
Not in our library10.1007/s00210-020-01935-w (opens in a new tab)
277.
Idro R., Marsh K., John C.C., Newton C.R. Cerebral malaria: Mechanisms of brain injury and strategies for improved neurocognitive outcome. Pediatr. Res. 2010;68:267-274.
Not in our library10.1203/pdr.0b013e3181eee738 (opens in a new tab)
278.
World Health Organization. Guidelines for the Treatment of Malaria. 2015.
Not in our library
279.
Padmakumar S., Jones G., Khorkova O., Hsiao J., Kim J., Bleier B.S., Amiji M.M. Osmotic core-shell polymeric implant for sustained BDNF AntagoNAT delivery in CNS using minimally invasive nasal depot (MIND) approach. Biomaterials. 2021;276:120989.
Not in our library10.1016/j.biomaterials.2021.120989 (opens in a new tab)
280.
Padmakumar S., Jones G., Pawar G., Khorkova O., Hsiao J., Kim J., Amiji M.M., Bleier B.S. Minimally Invasive Nasal Depot (MIND) technique for direct BDNF AntagoNAT delivery to the brain. J. Control. Release. 2021;331:176-186.
Not in our library10.1016/j.jconrel.2021.01.027 (opens in a new tab)
281.
Majumder J., Taratula O., Minko T. Nanocarrier-based systems for targeted and site specific therapeutic delivery. Adv. Drug Deliv. Rev. 2019;144:57-77.
Not in our library10.1016/j.addr.2019.07.010 (opens in a new tab)

Questions about this paper

We email you if it is retracted, withdrawn, corrected or flagged.

Reads

Read by people on this page

None yet.

Checked or read by AI through naulon

None yet.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.

Are you an author?

Is this your paper?

Claim it to add your note and be paid when agents cite it. Free.